At what cost is collagenase clostridium histolyticum viable for treating Peyronie's disease in a public healthcare system?
Andrology2020Vol. 8(5), pp. 1304–1311
Citations Over Time
Abstract
Central funding of collagenase in a public healthcare system would enable the management of Peyronie's disease to be moved to the outpatient setting. For this to be done at no additional cost to the NHS, it would require a cost reduction per vial of collagenase of £23.59 (4.1%), to a cost of £548.41.
Related Papers
- Repair of incisional hernias.(2001)
- → Pedicled Flaps for Lower Extremity Reconstruction in the Elderly(2004)9 cited
- → Surgical treatment of peyronie disease with dacron graft(1982)57 cited
- → Requirement and postoperative outcomes of abdominal panniculectomy alone or in combination with other procedures in a bariatric surgery unit(2010)14 cited
- → POS-01.89: Comparison of vitamin E and propionyl-l-carnitine, separately or in combination in patients with early chronic Peyronie’s disease: a double blind, placebo-controlled, randomized study(2007)1 cited